Trial shows effectiveness of hepatitis C drug telaprevir

04/7/2010 | Bloomberg Businessweek

About 50% of hepatitis C patients who did not respond to the standard treatment of peginterferon alpha plus ribavirin in the first round of therapy were virus-free six months after being treated with the two drugs plus telaprevir in the second round, according to a study. Only 14% of those who had the same two-drug treatment in the second round were virus-free after six months. Telaprevir presents an additional option for hepatitis C patients who do not respond to standard treatment, the lead author said.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA